Compass Pathways completed its new drug application for COMP360, its synthetic psilocybin for treatment-resistant depression, on November 9. Two days later at an investor conference, Chief Commercial Officer Lori Englebert and Chief Patient Officer Steve Levine described the road to first sales as a sequence in which each step waits on the last: an FDA action whose timing the company says it cannot predict, federal and state scheduling that it says must be final before much of its site work can start, and billing arrangements it says physicians need before they will prescribe. Management expects meaningful revenue to begin late in the second quarter of 2027 or in the third, with a slow first ramp.
By Compass’s account, the FDA review is active and much of the clinic infrastructure exists, and its written guidance, a launch in the first half of 2027 subject to FDA approval, is unchanged. A Reuters report the next day adds a question the November 11 remarks predate: whether the accelerated-review mechanics management described still operate.
FDA: an active review by Compass’s account, a contested voucher program, no date
Compass says it does not know whether FDA will accept the application with a review goal date or approve it without one, and that other voucher recipients received goal dates that FDA then beat. FDA’s voucher page, current as of October 19, lists approvals but no goal dates, still describes a one-to-two-month target, does not say what starts the clock, and says voucher applications face the same approval requirements as any other. Compass’s quarterly report says COMP360 may not receive a faster review than conventional procedures.
The executives described near-daily contact with the review division and said the information requests suggest FDA has finished much of its chemistry and preclinical review. FDA has not said so.
The next day, Reuters reported, citing six unnamed sources and internal documents, that FDA has shelved the voucher program: applications are still accepted but do not advance, and the political council that oversaw reviews is dormant. Two sources said career scientists have resumed overseeing review timelines for the nine holders that remain. Reuters did not name them or identify Compass or COMP360, and does not say Compass’s review or voucher is affected. HHS told Reuters the pilot is ongoing. FDA’s page, which predates the report, says nothing about a pause.
If FDA sets a priority-review goal date, its commitment for a new molecular entity is six months from the 60-day filing date: about July 8, 2027 for a November 9 completion (assuming COMP360 is treated as a new molecular entity). Compass described a date six months out.
Scheduling: a 90-day limit with a condition, and states Compass has not named
Compass says approval starts a 90-day statutory clock for the DEA. The statute sets one, but it runs from the later of the DEA’s receipt of HHS’s scheduling recommendation or of notice of FDA approval, so approval starts it only if the recommendation is already in hand. Compass has not said whether it is. It also says it filed its eight-factor analysis early and that this started the clock. The statute ties the clock to HHS and FDA, not to a sponsor’s filing, and Compass has not said what it submitted or to whom.
About 45 states, covering about 93 percent of the U.S. population, intend to reschedule within 30 days of the DEA, the company says. It has not named them, and an intention is not a legal commitment.
What the company says waits on final scheduling
Management said much of the site certification and training work cannot legally start until scheduling is final. The executives described a risk evaluation and mitigation strategy (REMS), an FDA-required safety program, in which sites, patients and specialty pharmacies would be certified. Compass has not described an FDA decision on one. Its quarterly report says only that it believes COMP360 would be subject to a REMS, and calls such programs costly and time-consuming for providers, a burden that could delay or limit commercialization.
The company says the rooms and monitoring staff at esketamine clinics convert directly to COMP360, though most heavy esketamine users have not been trial sites, Levine said. Behavioral Wire has examined that clinic base and how little of its terms are public.
Billing: the gate management named first
Englebert said uptake depends on patients being able to afford the drug and physicians being paid for monitoring time, about six hours per patient. Compass says Category III billing codes for that monitoring exist and fit the services, and have not progressed to Category I. The American Medical Association’s Category III codes for monitoring during psychedelic medication therapy are 0820T to 0822T, and CMS’s 2027 fee schedule lists them without a national payment rate, leaving the amount to regional contractors.
What management expects, and what it requires
Englebert said not to expect meaningful revenue until probably the third quarter, or late in the second quarter, of 2027, with uptake slow at first and then speeding up as prescribers feel trained, are paid for their time and schedule more patients. That places first revenue at or after the end of the first-half window in Compass’s written guidance.
Working backward shows what that requires. If the DEA used its full 90 days and states took the 30 days Compass cites, scheduling would take about four months after approval, so revenue by late June would need approval by roughly the end of February, before any time for the site certification management says follows scheduling. That is about three and a half months after completion: longer than FDA’s one-to-two-month voucher target, and months ahead of the July 8 goal date above. The revenue window depends on FDA acting early, and so in part on whether the accelerated-review mechanics management described still operate. Reuters’s sources say the program is not moving forward; HHS says the pilot is ongoing.
The next disclosures test the sequence: any FDA word on the voucher program or COMP360’s review timing, a goal date or approval, a DEA scheduling action, and the REMS and billing terms that come with a label.